ArticleACS medicinal chemistry letters2025

Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer Treatment.

Youichi Kawakita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.